The Hero proteins first came to wide scientific attention in 2020, when researchers in Japan described a widespread family of intrinsically disordered proteins that survive boiling and other harsh treatments that destroy most proteins. Despite lacking the stable three-dimensional folds that traditionally define functional proteins, Hero proteins act as chaperones, molecules that help other proteins maintain their proper shapes and avoid clumping together into toxic aggregates. Protein misfolding and aggregation are best known from neurodegenerative diseases such as Alzheimer’s and amyotrophic lateral sclerosis, but a growing body of evidence suggests they also play a role in the heart and blood vessels. Myocardial infarction has been shown to elevate endoplasmic reticulum stress and protein aggregation in heart tissue, and the RNA-binding protein TDP-43, a famous culprit in motor neuron disease, has been implicated in worsening atherosclerosis by promoting inflammation and lipid uptake in macrophages, the immune cells that populate arterial plaques.

Hero11 attracted particular interest because it has been shown to suppress the aggregation of TDP-43, and independent CRISPR screening work has identified C19orf53 as a gene required for cell proliferation through its connection to mTORC1, a central signaling complex that integrates nutrient and stress signals and is itself deeply entwined with obesity, metabolism, and plaque biology. That combination of chaperone activity, TDP-43 suppression, and mTORC1 involvement made C19orf53 a plausible, if speculative, player in cardiovascular disease. The Kursk team set out to test whether common genetic variation in the gene actually tracks with coronary artery disease in a human population.

To do so, the researchers genotyped seven single-nucleotide polymorphisms, SNPs, in C19orf53 in 2,164 unrelated individuals of Russian ethnicity from Central Russia. The cohort included 836 patients with established coronary artery disease and 1,328 healthy controls. They assessed associations with disease risk and clinical traits using regression analyses corrected for multiple testing by permutation, a statistical resampling approach that guards against false positives, and then used bioinformatic resources to annotate the variants for possible functional effects on gene regulation.

Two variants stood out. The SNP rs11666524, with the A allele as the effect allele, was associated with increased coronary artery disease risk with an odds ratio of 1.21 and a 95 percent confidence interval of 1.02 to 1.45, reaching a p-value of 0.04. The SNP rs2277947, also with the A allele, showed a similar signal, with an odds ratio of 1.22, a confidence interval of 1.01 to 1.46, and a p-value of 0.03. In genetic epidemiology, an odds ratio above 1 means that carriers of the effect allele face modestly elevated odds of disease compared with non-carriers, and the confidence intervals here exclude the null value of 1, though only narrowly, reflecting effects that are real but small, as is typical for common variants in complex disease.

Perhaps the most striking finding emerged when the team stratified the cohort by major cardiovascular risk factors. The strongest genetic effects appeared precisely in people without the usual risk drivers. Among non-smokers, three SNPs, rs10104, rs11666524, and rs2277947, showed significant associations with a p-value of 0.02. Among patients with normal fresh fruit and vegetable intake, rs10104 and rs346158 were significant at p equal to 0.02, while rs11666524 reached p equal to 0.016, rs2277947 p equal to 0.007, and rs8107914 p equal to 0.04. Among patients without obesity, rs10104 was significant at p equal to 0.02, rs11666524 at p equal to 0.01, rs346157 at p equal to 0.004, and rs2277947 at p equal to 0.01. In other words, the genetic contribution of Hero11 becomes most visible when the loud background noise of smoking, poor diet, and obesity is removed, a pattern known as gene-environment interaction in which lifestyle and metabolic factors mask or modify genetic effects.

This interaction pattern is not entirely new to the group. In earlier work, the same laboratory reported that obesity and environmental risk factors significantly modify the association between ischemic stroke and the Hero chaperone C19orf53, and they have documented links between other Hero family members, including C11orf58, or Hero20, C9orf16, also called bulbulin, and SERF2, and the risk of ischemic stroke. The new coronary artery disease findings extend that program from the brain’s vasculature to the heart’s, and they add a mechanistic thread: the study found that C19orf53 SNPs contribute to alterations in coagulation parameters, the laboratory measures of how readily blood clots. That connection matters because the clinical catastrophe in coronary artery disease is usually not the plaque itself but the thrombus that forms when a plaque ruptures, so genes that nudge coagulation could plausibly influence who converts stable atherosclerosis into a heart attack.

The bioinformatic annotation performed by the team points to possible regulatory mechanisms. Tools such as HaploReg and atSNP Search, which map variants onto chromatin states and transcription factor binding sites using data from resources like the GTEx atlas of genetic regulatory effects, allow researchers to ask whether disease-associated SNPs sit in regions that control gene expression. While the abstract does not identify a single causal variant or mechanism, the broader biological context is coherent: mTORC1 signaling regulates the mitochondrial integrated stress response, mTOR inhibition has been proposed as a strategy for stabilizing atherosclerotic plaques, and chaperone proteins such as Hsp27 and the co-chaperone BAG5, whose loss-of-function mutations cause dilated cardiomyopathy, have established roles in cardiovascular pathology. A chaperone gene wired into mTORC1 fits neatly into this landscape.

The study has clear limitations that temper enthusiasm. The association signals are modest, with p-values just under the conventional 0.05 threshold even after permutation correction, and the cohort is confined to individuals of Russian ethnicity from Central Russia, so replication in larger and more diverse populations will be essential before Hero11 can be considered an established coronary risk gene. The authors also received no external funding for the work, and the study was approved by the Ethical Review Committee of Kursk State Medical University, with all participants providing written informed consent. Still, the research was conducted under the Declaration of Helsinki and its statistical framework, using second-generation PLINK tooling, follows standard practice for candidate-gene association studies of this size.

What makes the work compelling is less any single odds ratio than the door it opens. Hero proteins were discovered only recently, and their chaperone-like activity in protecting cells against protein instability and aggregation suggests an entirely underexplored layer of cardiovascular biology, one that connects proteostasis, the cell’s system for managing protein folding, with the inflammatory and metabolic processes that drive atherosclerosis. If larger studies confirm that C19orf53 variants shape coronary risk and coagulation, the finding would join a growing list of hints that the heart’s health depends not only on lipids and blood pressure but also on how faithfully our cells keep their proteins in shape, and it would mark Hero11, a protein obscure enough to be named for its obscurity, as a genuine subject of cardiovascular genetics.

Subject of Research: Association of C19orf53 (Hero11) chaperone gene variants with coronary artery disease risk and coagulation traits

Article Title: The relationship between coronary artery disease and the heat-resistant obscure chaperone Hero11

Article References: Shilenok, V., Kobzeva, K., & Bushueva, O. (2026). The relationship between coronary artery disease and the heat-resistant obscure chaperone Hero11. Molecular Biology Reports, 53(1), Article 1684. https://doi.org/10.1007/s11033-026-12880-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12880-x

Keywords: coronary artery disease, C19orf53, Hero11, Hero proteins, molecular chaperones, genetic association study, coagulation, mTORC1, intrinsically disordered proteins, TDP-43, gene-environment interaction, cardiovascular genetics

Phase separation is the physical phenomenon by which a well-mixed solution splits into distinct phases, the way oil separates from vinegar in a shaken bottle of salad dressing. In cells, proteins containing intrinsically disordered, low-complexity domains can drive the formation of membraneless compartments called condensates, which concentrate specific molecules without any enclosing lipid membrane. Nucleoli, stress granules and nuclear speckles all form this way. The key property of healthy condensates is dynamism: molecules diffuse in and out, and the entire assembly can dissolve within seconds or minutes once conditions change. This liquid-like behavior depends on weak, multivalent interactions among the low-complexity domains, which constantly break and reform.

The trouble begins when those weak interactions stop being weak and transient. The review describes how, in ALS, condensates formed by RNA-binding proteins such as FUS and TDP-43 progressively lose their reversibility, maturing from liquid droplets into gel-like states and eventually into solid fibrillar aggregates that are hallmarks of the diseased motor neuron. This liquid-to-solid transition, sometimes called pathological hardening, is driven by the same low-complexity domains that make condensates form in the first place. Given time, the transient beta-sheet-like contacts within these domains can lock into stable structures, converting a dynamic organelle into an irreversible inclusion that the cell cannot dismantle.

What makes the new review distinctive is its emphasis on the layers of cellular regulation that normally prevent this maturation. The authors assemble evidence that molecular chaperones, best known for helping newly made proteins fold, also patrol condensates. Heat shock protein 70 family members, for example, can bind exposed hydrophobic stretches within condensates, remodel their internal organization and keep the assemblies fluid. Chaperone activity thereby extends the window in which a condensate remains reversible, buying the cell time to dissolve it before aggregation becomes permanent. When chaperone capacity is overwhelmed or declines, as it does with age and stress, that window narrows.

Nuclear import receptors form a second, perhaps more surprising, line of defense. Karyopherin-beta2, the receptor that ferries FUS into the nucleus, does more than transport. It binds directly to the proline-tyrosine nuclear localization signal within FUS and, in doing so, physically shields the low-complexity domain from engaging in the multivalent contacts that drive phase separation and fibrillization. In effect, the import receptor acts as a portable anti-aggregation chaperone, keeping FUS soluble during its journeys through the cytoplasm. The review highlights how this mechanism illustrates a broader principle: compact folded domains can modulate the behavior of disordered regions they are physically linked to or bound against.

The proteostasis network supplies a third layer of regulation. Enzymatic components such as protein disulfide isomerase and peptidyl-prolyl cis-trans isomerase A can alter the conformational state of proteins inside or near condensates, while ubiquilin-like protein 2, an ALS-linked protein, helps shuttle ubiquitinated cargo between condensates and the protein degradation machinery. Optineurin, another ALS-associated factor, participates in autophagic clearance of aggregates. Together these systems form a quality-control pipeline that continuously remodels and removes material from condensates, limiting the residence time of any given molecule and thereby reducing the probability that transient contacts will ripen into stable aggregates.

The review then turns to one of the most devastating genetic insults in ALS: the hexanucleotide repeat expansion in the C9ORF72 gene, the most common known cause of familial disease. This expansion produces arginine-rich dipeptide repeat proteins, and these short, highly basic peptides are potent modifiers of phase behavior. They can seed the condensation of RNA-binding proteins and, critically, impair nuclear import pathways, including the transport receptors that keep FUS in check. The result is a double hit: more condensation is promoted at the same time as the systems that would normally reverse it are disabled. The authors present this as a mechanistic explanation for why C9ORF72 pathology so closely resembles the FUS and TDP-43 proteinopathies seen across the ALS spectrum.

Perhaps the most forward-looking section of the review concerns zinc finger domains. Recent structural and biophysical studies suggest that these small, compact, folded modules can recognize specific polymer states of low-complexity domains and constrain their growth. Rather than dissolving condensates outright, zinc finger domains appear to cap or crosslink the polymers in ways that limit further elongation and material transition. This supports what the authors describe as a model in which structured domains act as modulators of higher-order assemblies, reading the physical state of a condensate and restraining its maturation. If confirmed across multiple ALS-associated proteins, this recognition mechanism could represent an entirely new regulatory vocabulary that cells use to manage their liquid organelles.

The therapeutic implications are considerable. Most ALS drug development has targeted downstream events, such as oxidative stress, excitotoxicity or the aggregates themselves. The framework laid out by the Nara Medical University team suggests an upstream strategy: preserve or restore condensate homeostasis. Enhancing chaperone activity, boosting nuclear import, supporting proteostasis components or mimicking the polymer-capping behavior of zinc finger domains could all, in principle, keep pathological proteins in their reversible, harmless state before fibrils ever form. Because the same regulatory principles appear to govern TDP-43, FUS and C9ORF72-related pathology, a therapy aimed at condensate homeostasis might cut across the genetic subtypes of the disease rather than addressing them one by one.

Cautious optimism is warranted. The review is a synthesis of mechanistic studies rather than a demonstration of efficacy in patients, and the authors themselves frame their conclusions as a model to be tested: clarifying how chaperones, import receptors, proteostasis enzymes and structured domains operate across ALS-associated proteins remains the task ahead. Yet the conceptual shift is hard to overstate. ALS, on this view, is not merely a disease of misfolded proteins but a disease of lost reversibility, in which the cell’s capacity to keep its own internal liquids liquid has been eroded. Understanding and reinforcing that capacity may prove to be one of the most promising directions in the search for effective treatments.

Subject of Research: Regulation of biological phase separation by molecular chaperones and related factors in amyotrophic lateral sclerosis

Article Title: Regulation of biological phase separation by molecular chaperones and related factors in amyotrophic lateral sclerosis

Article References: Regulation of biological phase separation by molecular chaperones and related factors in amyotrophic lateral sclerosis. (n.d.). https://doi.org/10.1186/s12916-026-05261-5

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05261-5

Keywords: amyotrophic lateral sclerosis, phase separation, molecular chaperones, TDP-43, FUS, C9ORF72, nuclear import, proteostasis, protein aggregation, RNA-binding proteins, zinc finger domains, condensates

The central player on the tumor side of this story is HSP90, a heat shock protein that functions as a molecular chaperone. Chaperones are the quality-control workers of the cell: they help newly made proteins fold into their correct three-dimensional shapes, stabilize damaged or mutated proteins that would otherwise be degraded, and buffer the cell against stresses ranging from heat to chemical toxicity. In cancer, HSP90 takes on an outsized role. Because tumor cells accumulate mutations and copy-number changes that produce unstable, misfolded proteins, they become unusually dependent on chaperone buffering to keep their aberrant signaling machinery running. This phenomenon, sometimes described as adaptive proteostasis buffering, allows evolving tumors to survive therapeutic pressure, including exposure to multikinase inhibitors used against hepatocellular carcinoma, the most common form of primary liver cancer.

The researchers asked a deceptively simple question: if HSP90 is what allows tumors to adapt under drug pressure, what happens to the tumor’s stress-response system when that buffering is deliberately disrupted? Using evolving tumor models of multikinase inhibitor-resistant hepatocellular carcinoma, together with patient-derived samples, they found that low-dose HSP90 inhibition produced a striking and precise effect. Rather than simply killing the cells or broadly denaturing their proteins, the treatment triggered the relocalization of a second chaperone, glucose-regulated protein 78, better known as GRP78, from its usual home in the endoplasmic reticulum to the outer surface of the tumor cell.

This relocalization matters because of where GRP78 normally sits. In healthy cells, GRP78 is an endoplasmic reticulum resident protein, part of the machinery that monitors protein folding inside the organelle and initiates the unfolded protein response when folding capacity is overwhelmed. It is not supposed to be visible on the cell surface. Yet under severe stress, some GRP78 escapes the endoplasmic reticulum and appears on the plasma membrane, where it can act as a signaling receptor and promote survival. Crucially, because surface GRP78 is absent from most normal adult tissues but enriched on stressed, evolving tumor cells, it has long been an attractive candidate target for antibody-based therapies. The problem has been getting enough of it onto the cell surface, reliably and selectively, to make such targeting effective.

The new study identifies the trafficking mechanism behind this relocalization. The researchers found that the movement of GRP78 to the tumor cell surface depends on DNAJC1, a member of the DnaJ heat shock protein family, also known as Hsp40. These co-chaperones typically assist HSP70-family proteins, and in this setting DNAJC1 appears to act as the trafficking factor that escorts GRP78 out of the endoplasmic reticulum and toward the plasma membrane when HSP90-dependent buffering is knocked down. When the team blocked HSP90 at low doses, the resulting proteostatic stress activated this DNAJC1-dependent route, converting GRP78 from an intracellular housekeeping protein into a surface-exposed marker of the stressed tumor state.

The authors give this relocalized protein a new conceptual name: a stress-induced tumor antigen, abbreviated SITA. The idea is that the very stress-response programs tumors deploy to survive therapy can be rewired so that they display targetable molecules on their surface. In other words, the adaptive machinery that normally confers drug resistance becomes a beacon for immune attack. This reframing is what distinguishes the study from earlier work on surface GRP78. Instead of relying on whatever baseline amount of the protein happens to be present on a tumor, the approach actively induces the antigen with a pharmacological intervention, then attacks it with engineered immune cells, creating a sequential strategy in which the first treatment sets up the second.

The immunological half of the strategy relies on CAR-based effector cells. Chimeric antigen receptors are synthetic receptors engineered into a patient’s own or donor-derived T cells or natural killer cells, allowing them to recognize a specific surface antigen and kill the cell carrying it. CAR-T cell therapies have produced dramatic results in blood cancers, but solid tumors have proven far harder, in part because researchers struggle to find antigens that are abundant on tumor cells and absent from essential healthy tissue. The Rutgers team generated GRP78-directed CAR-NK cells and tested them against tumor cells whose surface GRP78 had been induced by HSP90 inhibition. The stress-induced surface GRP78 made the resistant hepatocellular carcinoma cells markedly more susceptible to CAR-NK-mediated killing, turning a previously inaccessible intracellular chaperone into a legitimate immunotherapy target.

The findings were not confined to cell culture. In xenograft models, in which human tumor cells are implanted into immunodeficient mice, and in syngeneic models, in which intact immune systems are present, the combination of proteostasis perturbation and CAR-based therapy produced stronger anti-tumor effects than either approach alone. Disrupting the HSP90-GRP78 axis enhanced the activity of both CAR-NK and CAR-T cells. Perhaps most intriguingly, the treatment reshaped the tumor microenvironment itself: the researchers observed increased infiltration of natural killer cells and macrophages within tumor niches that expressed high levels of surface GRP78. This suggests that inducing the stress antigen does more than provide a docking site for engineered cells; it appears to create immunologically favorable niches that recruit and support innate immune players as well.

The clinical logic of the approach is worth unpacking. Multikinase inhibitor-resistant hepatocellular carcinoma represents a setting with few good options, and the study’s use of evolving, drug-resistant models means the strategy was tested against exactly the kind of tumors that defeat conventional targeted therapy. Because the HSP90 inhibitor is used at low doses, the goal is not maximal cytotoxicity, which has historically limited chaperone inhibitors in the clinic due to toxicity in normal tissues, but rather a calibrated perturbation that induces surface GRP78 without wholesale proteotoxic collapse. The selectivity then comes from the CAR step, since the engineered cells attack only cells displaying the induced antigen. In principle, this two-step design separates the toxicity of the sensitizing drug from the specificity of the immune kill.

As with any preclinical study, the path from these models to patients will require careful translation. Dosing schedules, the kinetics of GRP78 relocalization, the behavior of the strategy in heterogeneous human tumors, and the safety of combining chaperone inhibition with adoptive cell therapy all remain to be established in trials. The authors themselves frame the work as uncovering a previously unrecognized concept rather than a ready-made regimen. Still, the study, published open access on 3 October 2026 with the DOI 10.1186/s12943-026-02807-2, adds a genuinely new idea to the solid-tumor immunotherapy toolbox: that tumor evolution under therapeutic pressure, the very process that produces drug resistance, can be hijacked to display a stress-induced tumor antigen, and that CAR-engineered immune cells can be aimed at that antigen to destroy tumors that thought they had already adapted to everything medicine could throw at them.

Subject of Research: HSP90 inhibition induces DNAJC1-dependent GRP78 relocalization to the tumor cell surface, creating a stress-induced tumor antigen that enhances CAR-based immunotherapy in drug-resistant hepatocellular carcinoma.

Article Title: HSP90 inhibition drives GRP78 relocalization to potentiate CAR-based immunotherapy during tumor evolution

Article References: Sabha, Y., Cho, J. H., Zhang, X., Haggerty, J., Ai, A., Mayorga, A., Rajpoot, S., Chen, C.-H., Bulatowicz, J. J., Byrne, M., Cruz, M. A., Xynogala, A., Liu, C., Chen, F., Gause, W. C., Wang, X., Fu, K., Fritzky, L., Qin, Y., … Liu, D. (2026). HSP90 inhibition drives GRP78 relocalization to potentiate CAR-based immunotherapy during tumor evolution. Molecular Cancer. https://doi.org/10.1186/s12943-026-02807-2

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02807-2

Keywords: HSP90, GRP78, CAR-NK cells, CAR-T cells, hepatocellular carcinoma, proteostasis, molecular chaperones, tumor evolution, drug resistance, immunotherapy, DNAJC1, stress-induced tumor antigen

The system, developed by Yin Chen, Ke Zheng and colleagues at institutions across Guangxi, China, pairs a purpose-built expression plasmid called pSE2 with an auxiliary plasmid designated pRARE2a-GKJE. The design addresses a fundamental tension in plasmid-based expression: researchers want high copy numbers when preparing DNA for cloning, but low copy numbers during protein expression, when runaway replication amplifies leaky transcription and burdens the cell. Conventional expression plasmids lock users into a single copy-number regime, forcing compromises that either slow cloning workflows or degrade expression control.

The trick lies in a regulatory interplay mediated by two well-characterized bacterial proteins. The auxiliary plasmid supplies Rop, a small RNA-binding protein that represses replication of ColE1-family origins by stabilizing the interaction between RNA I and RNA II primers, effectively suppressing pSE2 copy number whenever the two plasmids coexist in the same cell. At the same time, the auxiliary plasmid delivers the LacI repressor at elevated levels, tightening transcriptional control over the expression cassette and further silencing basal transcription before induction. In practice, this means pSE2 can be propagated alone at high copy for efficient plasmid preparation, then be tamed by the companion plasmid once the two are brought together for expression.

Beyond replication and transcription control, pRARE2a-GKJE carries the cargo that directly attacks the solubility problem: rare transfer RNAs that compensate for codon bias in human-optimized genes, and molecular chaperones, including the GroEL-GroES and DnaK-DnaJ-GrpE systems indicated by the GKJE designation, that shepherd nascent polypeptides into their correct folds. Because previous auxiliary plasmids sharing the p15A origin and chloramphenicol marker could not be combined with one another, laboratories studying genes suffering from both codon bias and folding difficulty had no way to deploy tRNA supplementation and chaperone co-expression together. The new system resolves this incompatibility by consolidating all four functions, Rop, LacI, rare tRNAs and chaperones, onto a single companion plasmid.

The performance figures reported for challenging human-codon-optimized targets illustrate the payoff. TurboID, a promiscuous biotin ligase widely used in proximity labeling, reached 97 percent soluble expression. SpCas9, the genome-editing nuclease that has transformed molecular biology yet remains notoriously prone to misfolding in bacterial cytoplasm, achieved 99 percent solubility. PE6d, a prime-editing-associated protein, reached 53 percent soluble expression. For laboratories that routinely spend weeks optimizing induction conditions, strains and lysis protocols to rescue a few percent of soluble material from inclusion bodies, these numbers represent a substantial reduction in the trial-and-error burden of difficult-protein expression.

The copy-number dynamics add a second layer of practical value. During cloning, pSE2 maintained the high DNA yields that make plasmid preparation and downstream molecular work fast and economical. Upon co-expression with pRARE2a-GKJE, the plasmid population dropped markedly, minimizing leaky expression of products that may be toxic, membrane-active or proteotoxic even at basal levels. This conditional behavior, high copy when alone and suppressed copy in the expression strain, effectively decouples the cloning and expression phases of a project that conventional single-plasmid designs force into a single compromise.

One further feature broadens the system’s appeal beyond protein production. The authors report that pSE2 enables direct eukaryotic functional validation without re-cloning, meaning a construct prepared for bacterial expression can be carried forward into eukaryotic testing without the traditional subcloning step. For gene-editing reagents, proximity-labeling enzymes and other tools whose value depends on functional screening in eukaryotic cells, this removes an entire workflow bottleneck and reduces the opportunities for sequence errors and cloning artifacts to creep in along the way.

The significance of the work lies less in any single engineering novelty than in the integration. Rop-mediated copy-number control, LacI-mediated transcriptional tightening, tRNA supplementation and chaperone co-expression have each been explored individually over decades of E. coli expression research. By assembling them on a compatible two-plasmid chassis, the Guangxi team has converted a collection of partial fixes into a coherent platform that behaves rationally across the full life cycle of a construct, from plasmid prep through induction to eukaryotic validation. The system offers what the authors describe as a versatile platform for both recombinant protein production and functional studies.

The research was supported by funding from the Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region, the Natural Science Foundation of Guangxi Zhuang Autonomous Region, the National Natural Science Foundation of China, the Guangxi Qingmiao Talent Funding Project, the Guangxi Academy of Medical Sciences and the Guangxi Key Laboratory Operation Subsidy Project. Corresponding author Ke Zheng led the team alongside co-authors Yin Chen, Jialin Luo, Han Li, Zhuning Mo and Ben Huang. The article is published open access under a Creative Commons Attribution license, making the detailed protocols available to any laboratory seeking to adopt the system.

As demand grows for difficult-to-express proteins, from CRISPR effectors and base editors to engineered antibodies and proximity-labeling enzymes, tools that reliably deliver soluble, functional product from a cheap bacterial host carry broad relevance. If the reported solubility figures hold across a wider range of targets in other laboratories, the dual-plasmid system could become a standard fixture in expression workflows, shortening the path from gene sequence to functional protein for some of the most challenging molecules in modern biology.

Subject of Research: Development of a dual-plasmid system for soluble recombinant protein expression in Escherichia coli

Article Title: A dual-plasmid system for efficient soluble protein expression in Escherichia coli

Article References: Chen, Y., Luo, J., Li, H., Mo, Z., Huang, B., & Zheng, K. (2026). A dual-plasmid system for efficient soluble protein expression in Escherichia coli. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14039-x

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14039-x

Keywords: dual-plasmid system, Escherichia coli, recombinant protein expression, protein solubility, pSE2, pRARE2a-GKJE, molecular chaperones, rare tRNAs, leaky expression, codon bias, SpCas9, plasmid copy number